Current report No. 3/2024 – Informing about the medicinal product ZARIXA to the pharmaceutical market regulators

In reference to current report No. 24/2023, the Management Board of Celon Pharma S.A. (“Company”) of December 21, 2023 on the decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (“President of the Office for Registration of Medicinal Product”) concerning the issuance of a marketing authorization for one of the Company's products in the category of generic drugs in the area of cardiology, the Company’s Management Board wishes to inform that the President of the Office for Registration of Medicinal Product and to the Chief Pharmaceutical Inspector has received applications regarding the marketing authorization of ZARIXA (Rivaroxabanum) in the form of hard capsules, in the following dosages: 2,5 mg, 10 mg, 15 mg, 20 mg. The applications constitute a standard procedure element foreseen and required by pharmaceutical law.

This means that currently the Company is conducting activities aiming at providing availability of the aforementioned medicinal product in warehouses and pharmacies across Poland.